BPC-157: The Complete Guide to the Body Protection Compound

I've spent the better part of a decade following BPC-157 research, and I can tell you this: no other repair peptide generates the volume of consistent, multi-tissue preclinical data that this one does. Not TB-500. Not GHK-Cu. Not even growth hormone. If you're going to understand one peptide deeply, this is the one.

BPC-157 — Body Protection Compound-157 — is a 15-amino acid fragment derived from a protective protein found in human gastric juice. It's a pentadecapeptide, meaning exactly fifteen amino acids long, and it's been studied in over 100 preclinical trials spanning tendons, muscles, gut mucosa, nerves, bone, and even the brain. The consistency of the results across that range of tissue types is what makes it genuinely remarkable.

This is the article I've wanted to write for a long time. Not a summary, not a quick overview — the full picture. Where it came from, how it works, what the data actually says, where the regulatory landscape sits after the February 2026 HHS announcement, and what an honest reading of the safety conversation — including the cancer question — actually looks like.

BPC-157 is a naturally occurring gastric peptide fragment with demonstrated repair effects across at least six tissue types in preclinical models. Its mechanism involves simultaneous activation of VEGF, EGF, FGF, HGF, and nitric oxide pathways, which amounts to a multi-system approach to tissue repair that the Zagreb research group has spent over two decades documenting. The Wolverine Stack concept pairs it with TB-500 and GHK-Cu for three complementary repair mechanisms. The regulatory picture shifted in February 2026 when HHS Secretary Robert F. Kennedy Jr. announced that BPC-157 and roughly thirteen other peptides are expected to return to the FDA's Category 1 list — reopening licensed compounding-pharmacy access under physician prescription, though as of this writing the FDA has not yet published the formal updated list. The underlying research stands where it stood, but the safety conversation has matured, including a real debate about whether the same angiogenic mechanisms that drive repair could also feed undiagnosed tumors.

The pentadecapeptide: what BPC-157 actually is

A lot of the information circulating online gets the basics wrong. BPC-157 is not a synthetic invention. It's a fragment — specifically amino acids 249 through 263 — of a larger protein called BPC that your stomach naturally produces. This parent protein shows up in human gastric juice and appears to play a role in the gut's remarkable ability to repair itself.

The "pentadecapeptide" designation simply means it's 15 amino acids long. In the world of peptides, that's small. TB-500 is 43 amino acids, and insulin is 51. This small size has practical implications: BPC-157 is remarkably stable in acidic environments (which makes sense, given it originates in stomach juice), and it appears to retain biological activity when administered orally — something most peptides cannot do.

The sequence itself is GEPPPGKPADDAGLV. If you're wondering why a 15-amino acid sequence from your stomach can affect tendons, nerves, and bone tissue thousands of miles from the GI tract, you're asking the right question. The answer lies in the mechanism.

Why one peptide affects so many tissues

This is where BPC-157 gets genuinely interesting. Rather than acting on a single receptor or pathway, BPC-157 appears to orchestrate multiple repair systems simultaneously. Think of it less like a key fitting one lock, and more like a conductor bringing an orchestra into sync.

VEGF upregulation and angiogenesis

The most well-documented mechanism is BPC-157's upregulation of vascular endothelial growth factor (VEGF). VEGF is the primary signal your body uses to build new blood vessels. When you damage tissue, one of the first requirements for repair is restoring blood supply to the injured area. Without blood flow, you don't get oxygen, nutrients, or the immune cells needed for cleanup and rebuilding.

BPC-157 accelerates this process. Studies from the Zagreb group, published in journals including Life Sciences and the Journal of Physiology and Pharmacology, have repeatedly shown increased VEGF expression and new blood vessel formation at injury sites treated with BPC-157. This isn't subtle enhancement — in several animal models, the angiogenic response was significantly faster and more organized than in control groups.

This is probably the single most important thing BPC-157 does. Tissue repair is fundamentally a supply chain problem, and BPC-157 appears to solve the logistics first.

Growth factor receptor activation

Beyond VEGF, BPC-157 activates at least three additional growth factor pathways. EGF (epidermal growth factor) drives epithelial cell proliferation and differentiation, which is critical for skin healing and gut mucosal repair — the tissues that form the barriers between your insides and the outside world. FGF (fibroblast growth factor) stimulates fibroblast activity, the cellular machinery behind connective tissue production. Fibroblasts build collagen, produce extracellular matrix, and lay the structural foundation for tissue repair. When researchers see improved tendon and ligament healing with BPC-157, FGF activation is a major contributor. Then there's HGF (hepatocyte growth factor), which despite the name isn't limited to liver tissue. It plays a role in tissue repair across multiple organ systems, promotes cell survival under stress, and has anti-fibrotic properties — meaning it may help reduce scar formation during healing.

The simultaneous activation of these pathways explains why BPC-157 shows up in research on so many different tissue types. It's not doing one thing well — it's doing four things at once, and those four things happen to be the core requirements for tissue repair regardless of the tissue involved.

The FAK-paxillin pathway

More recent research has identified BPC-157's interaction with the focal adhesion kinase (FAK)-paxillin pathway. This is the signaling system that governs how cells attach to the extracellular matrix and organize themselves into functional tissue. When FAK-paxillin signaling is disrupted, cells can't properly adhere, migrate, or form organized structures.

BPC-157 appears to restore and enhance FAK-paxillin signaling at injury sites. In practical terms, this means cells in the repair zone can better attach where they need to be, organize into functional tissue architecture, and maintain structural integrity during the healing process. This may explain why BPC-157-treated tissue in animal studies tends to show more organized collagen alignment compared to controls — the cells are receiving better spatial instructions.

Nitric oxide modulation

BPC-157 interacts with the nitric oxide (NO) system in a way that's both protective and regulatory. NO is one of the body's primary signaling molecules for blood vessel dilation, inflammation modulation, and tissue protection. But the NO system is a double-edged sword — too little impairs circulation and healing, too much contributes to oxidative damage and excessive inflammation.

Research suggests BPC-157 has a modulatory effect on NO: it appears to normalize the system rather than simply pushing it in one direction. In conditions where NO is suppressed (like certain drug-induced injuries), BPC-157 restores NO production. In models of NO excess, it appears to bring levels down. This bidirectional modulation is unusual and may partially explain the compound's broad protective effects.

The Zagreb group: two decades of research

Any honest discussion of BPC-157 must acknowledge that the overwhelming majority of published research comes from one group: the laboratory of Dr. Predrag Sikiric at the University of Zagreb, Croatia. This group has been studying BPC-157 since the mid-1990s and has published well over 100 papers on the compound.

This concentration of research in one lab is simultaneously a strength and a limitation. The Zagreb group has built an extraordinarily detailed picture of BPC-157's effects across tissue types. Their methodology has been consistent, allowing meaningful comparisons across studies. They've investigated tendon, muscle, ligament, gut, nerve, bone, brain, and cardiovascular tissue — building a body of work that few other labs can match for a single compound.

On the limitation side, any time the majority of evidence comes from one research group, the scientific community rightfully asks whether results would replicate in independent labs. Independent replication studies have been published — and they generally support the Zagreb findings — but the volume doesn't approach what the Zagreb group has produced. More independent research is needed, and I think that's important to acknowledge clearly.

Key studies worth knowing

The Zagreb group demonstrated accelerated Achilles tendon healing in rats across multiple papers from 2003-2018, with BPC-157-treated subjects showing faster return to mechanical strength. The mechanism involved both VEGF-mediated angiogenesis and enhanced collagen deposition. A 2018 study showed improved tendon-to-bone healing specifically, which has relevance for rotator cuff and similar injuries.

The gut healing data, published across multiple years in the Journal of Physiology and Pharmacology, is perhaps the most intuitive application given BPC-157's gastric origin. Studies have shown protection against and healing of NSAID-induced gastric lesions, alcohol-induced damage, and inflammatory bowel disease models. The gut data is some of the most robust in the entire BPC-157 literature.

A 2019 nerve regeneration study showed improved sciatic nerve recovery in rat models, with both functional improvements (the animals regained more nerve function) and histological improvements (the nerve tissue itself looked better under microscopy). This expanded BPC-157 research beyond musculoskeletal and gut tissue into the nervous system. Bone healing studies demonstrated accelerated bone defect healing, with BPC-157-treated groups showing earlier mineralization and more organized bone formation compared to controls. More recent research has explored effects on dopaminergic pathways and potential neuroprotective properties, though this is a newer area and the evidence base is still developing.

Oral vs. injectable: the pharmacology debate

One of the most contested topics in the BPC-157 literature is the route of administration, and it matters more than people realize. The two routes are best understood as different conversations, not different doses of the same conversation.

The injectable case is the cleaner one. Subcutaneous injection bypasses digestion entirely and produces systemic distribution. Most of the Zagreb tendon, muscle, nerve, and bone studies used injectable administration, and that's where the bulk of the "BPC-157 helps tissue X" evidence comes from. If a study describes BPC-157 helping a tendon, ligament, or nerve injury, it almost certainly involved injection.

The oral case is where the disagreement lives. The Zagreb group has argued — based on the compound's gastric origin and inherent acid stability — that oral BPC-157 produces meaningful systemic effects, citing animal studies where oral administration influenced peripheral tissues. A more skeptical clinical reading, voiced by independent physicians reviewing the same literature, argues the opposite: that oral BPC-157 likely acts on the GI mucosa locally and clears before reaching systemic circulation in any biologically meaningful concentration, which would make oral primarily a gut-repair tool rather than a tendon tool.

The honest answer is that human pharmacokinetic data — the kind that would actually settle this — is essentially absent. What the literature supports clearly is oral BPC-157 for gastrointestinal applications: ulcer protection, IBD models, and gut-lining repair are among the most replicated findings in the entire dataset. What it supports less clearly is the idea that swallowing BPC-157 will heal a torn Achilles. That second claim depends on the systemic-absorption argument, and that argument is not as settled as the marketing implies.

Systemic vs. local effects

A fascinating aspect of BPC-157 research is the demonstration of systemic effects from local administration and vice versa. In several studies, injecting BPC-157 at a site distant from the injury still produced measurable healing effects. And oral administration has shown effects on peripheral injuries, not just the GI tract.

This suggests that BPC-157's mechanisms are not purely local. The compound appears to influence systemic repair signaling — possibly through its effects on the NO system, growth factor expression, or both. Some researchers have proposed that BPC-157 may interact with the gut-brain axis, providing a communication pathway between gastrointestinal and peripheral tissues. This is speculative but not unreasonable given the compound's gastric origin.

The Wolverine Stack: BPC-157 + TB-500 + GHK-Cu

If you spend any time in the peptide research community, you've encountered the term "Wolverine Stack." The name is admittedly dramatic, but the underlying rationale is sound: three peptides with complementary mechanisms of tissue repair, often discussed together because each addresses a different phase or requirement of the healing process. This section is a mechanism comparison — not a protocol.

BPC-157 handles angiogenesis and growth factor activation. It builds new blood supply and activates the growth signals needed for tissue repair — building the roads and sending the work orders. TB-500 (Thymosin Beta-4) drives cell migration. Through its interaction with actin, TB-500 enables repair cells — fibroblasts, immune cells, stem cells — to physically move to the injury site. BPC-157 builds the roads; TB-500 gets the workers there. GHK-Cu activates gene expression for tissue remodeling. It upregulates over 4,000 genes involved in tissue repair, collagen synthesis, and anti-inflammatory responses. If BPC-157 handles logistics and TB-500 handles transport, GHK-Cu is reprogramming the cells to actually do the rebuilding work more effectively.

Each compound addresses a different bottleneck in the repair process. Angiogenesis alone doesn't help if repair cells can't migrate to the site. Cell migration doesn't help if the cells aren't expressing the right repair genes. Gene activation doesn't help without blood supply. The three-compound framing is a way to see how those bottlenecks relate — it is not a usage recommendation.

Is this concept proven in clinical trials? No. The stack rationale is based on the individual mechanisms of each compound and the logical complementarity of those mechanisms. But the mechanistic reasoning is strong, and practitioner observations have kept the concept in active discussion in the research community.

For the broader question of how peptide stacking works as a principle — including the CJC-1295 + Ipamorelin GHRH/GHRP synergy and why complementary mechanisms outperform single-pathway approaches — the peptide stacking guide covers it.

The FDA story: from 2023 restriction to the February 2026 pivot

The regulatory history matters for understanding where BPC-157 actually sits today, because the headlines have moved in opposite directions inside three years.

In 2023, the FDA placed roughly nineteen widely used peptides — BPC-157 among them — onto the Category 2 list of the interim 503A Bulks List. Category 2 means the FDA has identified safety concerns or insufficient data and is restricting use in pharmacy compounding. The practical effect: licensed U.S. compounding pharmacies that had been preparing BPC-157, TB-500, CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604 and others for patients with physician prescriptions could no longer legally do so. The cited rationale centered on immunogenicity concerns, peptide-related impurities, and limited human safety data. In September 2024, the FDA pulled five of those peptides back off Category 2 after the original nominators withdrew their petitions — that batch included AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate.

On February 27, 2026, during an episode of The Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. announced that approximately fourteen of the originally restricted peptides — BPC-157 included — are expected to move back to Category 1, the status that permits licensed compounding pharmacies to prepare them under physician prescription. Subsequent reporting from BioPharma Dive and Frier Levitt (the regulatory law firm tracking this closely) indicated the underlying mechanism was that nominators of those peptides withdrew their Category 2 petitions, with the substances coming off Category 2 in April 2026 and the FDA's Pharmacy Compounding Advisory Committee scheduled to formally review compounding status at its July 23–24, 2026 meeting.

Three things matter here, and they tend to get blurred together.

First, this is announced direction, not finalized rule. As of this writing the FDA has not published a formal updated list naming each peptide moving back to Category 1. Reporting varies between "twelve" and "fourteen" peptides depending on which counting convention is used. Treat the situation as an evolving regulatory pivot, not a settled state.

Second, Category 1 is not FDA approval. None of these peptides have been approved as drugs. What Category 1 status allows is access through licensed compounding pharmacies under a valid physician prescription — a narrow, supervised channel, not over-the-counter availability and not a stamp of efficacy. If anyone tells you "BPC-157 is now FDA-approved," that is wrong.

Third, the grey market is unaffected. The websites selling BPC-156 vials labeled "research use only, not for human consumption" were illegal before the 2023 restriction, they remained illegal during it, and they remain illegal now. Reclassification doesn't change the law around unregulated peptide sales, and it doesn't change the very real purity and dosing-accuracy problems that come with sourcing from unregulated suppliers.

The underlying research data is unchanged through all of this. The Zagreb studies, the mechanism papers, the independent replications — none of that moved. What moved is which legal channel patients have to access a properly prepared, properly dosed product under medical supervision.

Safety: the angiogenesis and cancer question

This is the section that most clinic websites skip. I'm going to walk through it carefully because anyone considering BPC-157 deserves to understand what the actual debate is.

The mechanisms that make BPC-157 useful for repair — VEGF upregulation, FAK-paxillin signaling, accelerated angiogenesis — are not benign in every biological context. They are the same mechanisms tumors hijack to grow blood supply and metastasize. Increased FAK phosphorylation is associated with epithelial-mesenchymal transition, lymph node metastasis, and worse outcomes across multiple cancer types. VEGF/VEGFR2 signaling is active in roughly half of human cancers, and anti-VEGF drugs (bevacizumab being the best-known example) exist specifically to shut that signaling down. The theoretical concern, which serious reviewers have raised in print, is that giving a pro-angiogenic, pro-FAK compound to a person with a small, undetected tumor could provide that tumor with growth and migration advantages it would not otherwise have.

The counter-argument comes from the Zagreb group itself. In a 2025 comment published in Pharmaceuticals, Sikiric and colleagues argued that BPC-157 selectively targets pathological angiogenesis while preserving the protective vascular functions tissues need to heal, and they pointed to a 2004 in vitro study showing BPC-157 inhibited VEGF signaling in a human melanoma cell line via the MAPK pathway as evidence of anti-tumor potential. A 2025 reply in the same journal from Józwiak and colleagues pushed back hard: that 2004 melanoma study has not been independently replicated, and there are no published in vivo tumor-growth or metastasis studies — in either direction — that would let us actually answer the question. The reply also noted that more than eighty percent of the roughly 190 BPC-157 papers in PubMed list Sikiric or Seiwerth as authors, which is a real concern for any compound where independent replication is the standard of evidence.

Reading the literature honestly, here is where it lands: no published study demonstrates that BPC-157 causes cancer in humans, and no published in vivo study demonstrates that it suppresses cancer either. The mechanistic concern is real and grounded in well-established tumor biology. The reassurance that "it only targets pathological angiogenesis" is grounded in a single twenty-year-old cell-line experiment and the Zagreb group's own mechanistic interpretation. Those are not the same standard of evidence.

The practical takeaway for anyone with an active cancer diagnosis, a history of cancer in remission, an elevated genetic risk (BRCA, Lynch, etc.), or unexplained symptoms that haven't been worked up: this is a compound to discuss with an oncologist before considering, not a compound to self-experiment with based on a tendon issue. The risk-benefit math for a healthy thirty-year-old with a sports injury is genuinely different from the risk-benefit math for someone in cancer surveillance. Conflating the two is what the marketing tends to do, and it is not honest.

What the human evidence actually looks like

People ask me what the studies say. The honest answer is that almost all of the studies are in rats, and that needs to be stated clearly.

The preclinical body of work is extensive. Over a hundred animal studies, primarily rodent, spanning tendons, ligaments, muscle, gut mucosa, peripheral and central nervous system tissue, bone, and cardiovascular tissue. The consistency across tissue types is the part that has kept serious researchers interested for two decades. The 2025 narrative review by McGuire and colleagues in PMC and the Vasireddi sports-medicine review in PubMed both walk through that animal evidence in detail and reach similar conclusions: promising signal, mechanism plausible, human translation unproven.

The human evidence is much thinner. There is a small pilot using a related compound (PL 14736) in inflammatory bowel disease that produced encouraging results. There is a registered clinical trial (NCT07437547) currently studying BPC-157 for acute hamstring strain repair. There are published case reports and clinician observations, which are useful for hypothesis generation but do not constitute controlled evidence. There are no large, double-blind, placebo-controlled human trials of BPC-157 for any of its commonly marketed uses. Anyone telling you "the human studies show" is overstating what is on the page.

This is not a reason to dismiss the compound. It is a reason to be precise about what is known versus what is hoped.

Realistic timelines: what the literature actually suggests

"How long does it take to kick in" is one of the most-searched BPC-157 questions, and the literature gives a partial answer.

In the animal models where BPC-157 has been studied, measurable changes in tissue healing markers tend to appear within days of starting administration in acute injury models — accelerated angiogenesis at day three to five, improved collagen organization by the second week, more complete tendon-to-bone integration in the three-to-eight-week range depending on the injury severity. Gut models tend to show protective effects very quickly because the tissue turnover is faster.

The honest extrapolation to humans is that this is an extrapolation. Animal healing timelines do not map cleanly onto human tissues, particularly chronic human tendinopathies that may have been present for months or years before treatment. A clinician familiar with this space will typically describe a multi-week window to even start evaluating whether something is working in a chronic tendon presentation, not an overnight result. People expecting day-three relief from a two-year-old shoulder problem are working from internet promise, not from the actual data.

What the literature does not support is the idea of a fast subjective "feeling" of being on BPC-157. Unlike compounds that act on neurotransmitter or hormonal pathways, BPC-157's effects are at the tissue-repair level — they show up in healing trajectories, not in mood, energy, or acute symptom relief on day one. If somebody describes BPC-157 making them feel different within hours, the most parsimonious explanation is placebo, not pharmacology.

Honest limitations

I wouldn't be doing my job if I didn't lay this out clearly.

Most evidence is preclinical. The overwhelming majority of BPC-157 research has been conducted in animal models — primarily rats. We do not have large-scale, double-blind, placebo-controlled human clinical trials. This is the single most important limitation of the current evidence base.

Most research comes from one group. While the Zagreb laboratory's work is prolific and their methodology is solid, the relative scarcity of fully independent replication studies is a legitimate concern. Science depends on reproducibility, and more independent labs need to investigate these findings. The replication issue is the same issue that drives the cancer question above — when one group produces most of the evidence, you need outside confirmation for the high-stakes claims in either direction.

The mechanism is complex and not fully mapped. While we understand the major pathways (VEGF, EGF, FGF, HGF, NO, FAK-paxillin), the complete mechanism of action — including how BPC-157 interacts with receptor systems and what its primary binding target is — remains an active area of investigation.

Long-term safety data is limited. Preclinical studies have not identified significant toxicity, and BPC-157 has been described as having no known LD50 (lethal dose), which is unusual. But "no identified toxicity in animal studies" is not the same as "proven safe for long-term human use." These are different standards of evidence. Dosing in humans is not standardized — without formal clinical trials, any human dosing protocol is extrapolation rather than validated dose-response data.

I find BPC-157 one of the most interesting repair compounds in the current research pipeline. I also find that intellectual honesty about the evidence base — including the cancer question that the marketing tends to skip — is more valuable than overpromising. Both things can be true at the same time.

Frequently asked questions

What makes BPC-157 different from other repair peptides?

Two things: the breadth of tissue types it affects and the multi-pathway mechanism. Most repair compounds work on one or two pathways. BPC-157 simultaneously activates VEGF, EGF, FGF, and HGF while modulating the nitric oxide system. This multi-pathway approach is why it shows up in research on tendons, gut, nerve, muscle, bone, and brain tissue — a range that's unusual for a single compound.

Is BPC-157 the same as the protein found in stomach juice?

Not exactly. BPC-157 is a fragment — 15 amino acids extracted from the much larger BPC protein in gastric juice. The full protein is too large and complex to use directly, but this specific fragment retains the biological activity relevant to tissue repair. Think of it as isolating the active ingredient from a larger molecule.

Is BPC-157 a peptide or a steroid?

A peptide. BPC-157 is a 15-amino acid short peptide. It is not a steroid hormone, does not bind to androgen receptors, and has no relationship to anabolic steroids. People confuse the two because both show up in athletic and recovery contexts, but the biochemistry is completely different.

How long does BPC-157 take to work?

In animal models, measurable tissue-healing changes appear within days for acute injuries, with more complete repair over three to eight weeks depending on the tissue. Human chronic injuries do not necessarily map onto those timelines, and clinicians familiar with the compound generally describe a multi-week evaluation window rather than overnight changes. BPC-157 acts at the tissue-repair level, not on mood or acute pain pathways — anyone describing a fast subjective effect is most likely describing placebo.

Does BPC-157 cause cancer?

There is no published study showing BPC-157 causes cancer in humans, and there is no published in vivo study showing it suppresses cancer either. The mechanistic concern is real: BPC-157's pro-angiogenic and FAK-paxillin signaling are the same mechanisms tumors use to grow and metastasize. The Zagreb group has argued the compound targets pathological angiogenesis selectively, but that defense rests on a single un-replicated 2004 melanoma cell-line study. The honest position is uncertainty. Anyone with an active cancer, a cancer history, or elevated genetic risk should discuss this compound with an oncologist before considering it.

Can BPC-157 be taken orally?

It depends what you're using it for. The strongest case for oral BPC-157 is gastrointestinal — ulcer protection, IBD models, and gut-lining repair are well replicated in preclinical work. The case for oral BPC-157 producing meaningful systemic effects (tendon, ligament, nerve) is contested: the Zagreb group argues oral works systemically based on the compound's gastric origin and acid stability, while more skeptical clinical readers argue oral BPC-157 likely acts locally on the gut and clears before reaching peripheral tissues in biologically meaningful amounts. Human pharmacokinetic data is essentially absent, which is why this remains a debate rather than a settled point.

How does the Wolverine Stack actually work?

The concept addresses three different bottlenecks in tissue repair simultaneously. BPC-157 builds new blood vessels to the injury. TB-500 enables repair cells to migrate to the injury site through actin regulation. GHK-Cu activates thousands of genes involved in tissue remodeling and collagen synthesis. Each handles a different phase of repair. Treat the stack as a framework for understanding the relationship between three mechanisms — not as a usage recommendation.

What changed with the FDA in February 2026?

In 2023, the FDA placed BPC-157 on its Category 2 restricted list, which stopped licensed compounding pharmacies from preparing it. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that BPC-157 and approximately thirteen other peptides are expected to move back to Category 1, reopening that compounding-pharmacy channel under physician prescription. As of this writing the FDA has not published the final updated list, and the Pharmacy Compounding Advisory Committee is scheduled to review the status formally in July 2026. Important caveats: Category 1 is not FDA drug approval, the change does not legitimize grey-market "research use only" sales, and reporting varies between twelve and fourteen peptides depending on the source.

Why is most BPC-157 research from one laboratory?

The University of Zagreb laboratory under Dr. Predrag Sikiric has been the primary research group studying BPC-157 since the 1990s. They've built the most comprehensive body of work on any single peptide that I'm aware of. More than eighty percent of the roughly 190 BPC-157 papers in PubMed list Sikiric or Seiwerth as authors. Independent replication studies exist and generally support the broad findings, but the field would benefit from more independent groups investigating both the efficacy and the safety questions. This is a fair criticism, and the scientific community acknowledges it.